5 completed, 3 terminated, 1 active not recruiting, 1 not yet recruiting. 9 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Toll-Like Receptor 1: new trials by email Literature Review of Toll-Like Receptor 1 trials Research Report on Toll-Like Receptor 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma Tumor Tissue Sampling, Lymphodepletion Conditioning, Infusion of HS-IT101 Injection - Melanoma (Excluding Uveal Melanoma) | Phase 2 | Not yet recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 90 | 2026-02-26 | 2026-02-12 |
| A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors TBio-4101, Pembrolizumab - Breast Cancer, Colorectal Cancer | Phase 1 | Terminated | Turnstone Biologics, Corp. | 31 | 2023-01-17 | 2025-03-10 |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer LN-145 - Metastatic Non Small Cell Lung Cancer | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 170 | 2021-05-07 | 2026-06-26 |
| TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors TIL injection - Solid Tumors, Adult | Phase 1 | Active not recruiting | Grit Biotechnology | 12 | 2021-04-21 | 2026-09-18 |
| Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer Tumor infiltrating lymphocytes (TIL) LN-145 - Metastatic Triple Negative Breast Cancer | Phase 2 | Completed | Yale University | 6 | 2019-12-23 | 2024-11-21 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Lifileucel, LN-145, Pembrolizumab - Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | Iovance Biotherapeutics, Inc. | 225 | 2019-05-07 | 2026-05-15 |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer LN-145, Durvalumab - Non Small Cell Lung Cancer | Phase 2 | Withdrawn | Iovance Biotherapeutics, Inc. | 2018-02-28 | 2019-04-16 | |
| Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients TIL + IL-2 + Nivolumab - Melanoma | Phase 1 / Phase 2 | Unknown | Nantes University Hospital | 11 | 2018-02-12 | 2022-05-06 |
| Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma LN-145, LN-145 + pembrolizumab - Cervical Carcinoma | Phase 2 | Terminated | Iovance Biotherapeutics, Inc. | 210 | 2017-06-22 | 2026-09-25 |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck LN-145, LN-145-S1 - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Completed | Iovance Biotherapeutics, Inc. | 64 | 2017-01-09 | 2023-10-12 |
| Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion - Metastatic Melanoma | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 13 | 2012-10-09 | 2025-12-19 |
| Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma Melanoma Reactive TIL, Cyclophosphamide, IL-2 - Metastatic Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2006-04-01 | 2012-10-18 |
| Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma TIL + IL2 - Melanoma | Phase 3 | Completed | Nantes University Hospital | 70 | 2005-05-01 | 2017-06-01 |
Melanoma (7) · Carcinoma, Non-Small-Cell Lung (4) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Skin Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1) · Uveal Melanoma (1)
Iovance Biotherapeutics, Inc. (5) · Nantes University Hospital (2) · Grit Biotechnology (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hangzhou Huasai Biomedicine Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Turnstone Biologics, Corp. (1) · Yale University (1)
United States (9) · France (4) · Canada (3) · Germany (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · Italy (2) · Netherlands (2) · Australia (1) · China (1) · Greece (1) · Singapore (1) · South Korea (1)
Amod Sarnaik, M.D. (1) · Ines Verdon, MD (1) · Michael Hurwitz, MD (1) · Steven A Rosenberg, M.D. (1)
PMID 22555974, PMID 35880940, PMID 35880942, PMID 40854613
2016 (1), 2018 (1)